Author

Kiersten Jensen

Institutions: University of Minnesota, Masonic Cancer Center

Observed institutions: University of Minnesota, Masonic Cancer Center

OpenAlex ID: A5087054026

Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study

2014 · Cheryl A. London, Luis Feo Bernabe, et al. · PLoS ONE · 101

Results of a Phase I Dose Escalation Study of the Novel, Oral CRM1 Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Spontaneous Non-Hodgkin's Lymphomas (NHL)

2012 · Sharon Shacham, Sandra Barnard, et al. · Blood · 8

Abstract 3809: Evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in spontaneous canine cancer: Results of phase I and phase II clinical trials

2014 · Cheryl A. London, Luis Feo Bernabe, et al. · Cancer Research · 3

Evaluation Of The Novel, Orally Bioavailable Selective Inhibitor Of Nuclear Export (SINE) Verdinexor (KPT-335) In Spontaneous Canine Cancer: Results Of Phase I and Phase II Clinical Trials

2013 · Cheryl London, Luis feo Bernabe, et al. · Blood · 2

Works count: 4

Citation count: 114

H-index: 3

I10-index: 1